Concepedia

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia

Zheng Hu, Xiaofen Pan, Fuqun Wu, Liyuan Ma, Dapeng Liu, Ying Liu, Tingting Feng, Fan‐Yi Meng, Xiaoli Liu, Qianli Jiang,

PLoS ONE · 2009 · 43 citations · 64 references

DOIFull text

Open access

Abstract

These data suggest that combined use of tyrosine kinase inhibitor and proteasome inhibitor might be helpful for optimizing CML treatment.

References

64

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Brian Druker, Moshe Talpaz, Debra Resta et al. · New England Journal of Medicine · 2001 · 5.2K citations · Full text

β-Catenin regulates expression of cyclin D1 in colon carcinoma cells

Osamu Tetsu, Frank McCormick · Nature · 1999 · 3.6K citations

, , +10

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Stephen G. O’Brien, François Guilhot, Richard A. Larson et al. · New England Journal of Medicine · 2003 · 3.5K citations · Full text

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

Brian Druker, Charles L. Sawyers, Hagop M. Kantarjian et al. · New England Journal of Medicine · 2001 · 2.7K citations · Full text